APA

Chan D. W., Kelley C. A., Ratliff T. L., D'Agostino D., Ritchey J., Lamb D. J., Beck J., Lott N., Wener M. H., Daum P., Henkin R. E., Kaske D. N., Golightly D. W., McBride J., Layco G., Ota M. K., Tanasijevic M. J., Grudzien C., Woodrum D. L., Bray K. R., Southwick P. C., Gasior G. H. & Loveland K. G. (19991021). Analytical and clinical performance characteristics of Hybritech's Tandem-R free PSA assay during a large multicenter clinical trial to determine the clinical utility of percentage of free prostate-specific antigen. : Clinical chemistry.

Chicago

Chan D W, Kelley C A, Ratliff T L, D'Agostino D, Ritchey J, Lamb D J, Beck J, Lott N, Wener M H, Daum P, Henkin R E, Kaske D N, Golightly D W, McBride J, Layco G, Ota M K, Tanasijevic M J, Grudzien C, Woodrum D L, Bray K R, Southwick P C, Gasior G H and Loveland K G. 19991021. Analytical and clinical performance characteristics of Hybritech's Tandem-R free PSA assay during a large multicenter clinical trial to determine the clinical utility of percentage of free prostate-specific antigen. : Clinical chemistry.

Harvard

Chan D. W., Kelley C. A., Ratliff T. L., D'Agostino D., Ritchey J., Lamb D. J., Beck J., Lott N., Wener M. H., Daum P., Henkin R. E., Kaske D. N., Golightly D. W., McBride J., Layco G., Ota M. K., Tanasijevic M. J., Grudzien C., Woodrum D. L., Bray K. R., Southwick P. C., Gasior G. H. and Loveland K. G. (19991021). Analytical and clinical performance characteristics of Hybritech's Tandem-R free PSA assay during a large multicenter clinical trial to determine the clinical utility of percentage of free prostate-specific antigen. : Clinical chemistry.

MLA

Chan D W, Kelley C A, Ratliff T L, D'Agostino D, Ritchey J, Lamb D J, Beck J, Lott N, Wener M H, Daum P, Henkin R E, Kaske D N, Golightly D W, McBride J, Layco G, Ota M K, Tanasijevic M J, Grudzien C, Woodrum D L, Bray K R, Southwick P C, Gasior G H and Loveland K G. Analytical and clinical performance characteristics of Hybritech's Tandem-R free PSA assay during a large multicenter clinical trial to determine the clinical utility of percentage of free prostate-specific antigen. : Clinical chemistry. 19991021.